JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In continuation of our letter dated January 23, 2020, we enclose copies of the advertisements published on January 24, 2020, in MINT (English) and HINDUSTAN (Hindi) with respect to notice of the Board Meeting scheduled to be held on January 31, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Unaudited Financial Results For The Quarter Ended December 31, 2019
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on January 31, 2020 after submission of the financial results for the quarter ended December 31, 2019 to the Stock Exchanges. Details of the Conference Call are attached. This is for information and record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - January 31, 2020
JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2020 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, January 31, 2020, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended December 31, 2019. This is for information and record.
Hot Stocks | Here's why you can buy Jubilant Life Sciences for a short term
The theme of this month has been the mid and small-caps, which outperformed benchmarks with a huge margin. JUBILANT LIFE SCIENCES LIMITED - 530019 - Shareholding for the Period Ended December 31, 2019
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here Jubilant Life Sciences Ltd - 530019 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer Jubilant Life Sciences Ltd - 530019 - Intimation Pursuant To Regulation 57(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In continuation of our letter dated December 30, 2019, we wish to inform you that the Company has on January 7, 2020, redeemed its Non-Convertible Debentures along with accrued interest thereon, as per the attached details. This is for your information and record. JUBILANT LIFE SCIENCES LIMITED - 530019 - Early Redemption Of Non-Convertible Debentures
In continuation of our letter dated December 11, 2019, we wish to inform you that the Committee of the Board of Directors has, at its meeting held on December 30, 2019, approved the early redemption of Non-Convertible Debentures of Rs. 745 Crore of the Company. The same shall be paid on January 7, 2020. Jubilant Life Sciences Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we wish to inform that share certificates have been reported to be lost by Mr. Manjit Sodhi son of Mrs. Ripudaman Kaur Sodhi, Shareholder as stated in the enclosed letter. Jubilant Life Sciences Ltd - 530019 - Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company would remain closed for 'Designated Persons' from Wednesday, December 25, 2019 till 48 hours after announcement of the financial results for the quarter ending December 31, 2019 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of Trading Window.